16492-28-7

Basic information

• Product Name: METHYL 2,4-DICHLOROPYRIMIDINE-6-CARBOXYLATE
• Synonyms: 2,6-DICHLORO-4-PYRIMIDINE CARBOXYLIC ACID METHYL ESTER;NSC46804;2,6-DICHLORO-PYRIMIDINE-4-CARBOXYLIC ACID;4-PyriMidinecarboxylic acid, 2,6-dichloro-;2,6-DICHLORO-4-PYRIMIDINE CARBOXYLIC ACID;2,6-DichloropyriMidin-4-carboxylic acid;2,4-Dichloropyrimidine-6-carboxylic acid;Methyl 2,6-dichloro-4-pyrimidinecarboxylate
• CAS NO: 16492-28-7
• Molecular Formula: C₅H₂Cl₂N₂O₂
• Molecular Weight: 192.99
• Mol File: 16492-28-7.mol
• Article Data: 5

Chemical Properties

• Melting Point: 54-56°C
• Boiling Point: 374.9 °C at 760 mmHg
• Flash Point: 180.5 °C
• Appearance: /
• Density: 1.718 g/cm³
• Vapor Pressure: 2.76E-06mmHg at 25°C
• PKA: 2.07±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: METHYL 2,4-DICHLOROPYRIMIDINE-6-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2,4-DICHLOROPYRIMIDINE-6-CARBOXYLATE(16492-28-7)
• EPA Substance Registry System: METHYL 2,4-DICHLOROPYRIMIDINE-6-CARBOXYLATE(16492-28-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/38
• Safety Statements: 26
• WGK Germany: 3
• HazardClass: IRRITANT, KEEP COLD
• Hazardous Substances Data: 16492-28-7(Hazardous Substances Data)

Usage

Uses

2,6-Dichloropyrimidine-4-carboxylic acid is used as pharmaceutical intermediate.

InChI:InChI=1/C5H2Cl2N2O2/c6-3-1-2(4(10)11)8-5(7)9-3/h1H,(H,10,11)/p-1

Upstream product

• 65-86-1 2,4-dihydroxypyrimidine-6-carboxylic acid 
• 65-86-1 orotic acid 
• 24598-73-0 potassium hydroorotate 
• 10026-13-8 phosphorus pentachloride 
• 10025-87-3 trichlorophosphate 

Downstream Products

• 16490-14-5 2,4-diaminopyrimidine-6-carboxylic acid 
• 1186423-97-1 C₁₂H₉ClN₂O₂S 
• 1218996-35-0 C₁₆H₁₈ClN₃O₂ 
• 26830-94-4 2,4-dichloropyrimidine-6-carboxylic acid chloride 
• 6299-85-0 2,6-dichloropyrimidine-4-carboxylic acid methyl ester 
• 1215029-06-3 6-[5-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenylaminocarbonyl)-2-methyl-phenoxy]-pyrimidin-4-carboxylic acid-methylamide 
• 1159007-08-5 2-{1-[6-(1,3-dihydro-isoindole-2-carbonyl)-pyrimidin-4-yl]-piperidin-4-yl}-5-phenyl-2,4-dihydro-1,2,4-triazol-3-on 
• 2338747-54-7 N-[(2S)-1-hydroxypropan-2-yl]-2-(pyridin-3-yl)-6-[4-(trifluoromethoxy)phenyl]pyrimidine-4-carboxamide 

Relevant articles and documents

RAS INHIBITORS AND METHODS OF USING THE SAME

Provided herein are compounds identified as inhibitors of KRAS protein activity that can be used to treat various diseases and disorders, such as cancer.

Design, synthesis and evaluation of novel derivatives of orotic acid amide as potent glucokinase activators

Background: Glucokinase activators (GKAs) represent a promising opportunity for the treatment of type 2 diabetes due to the fact that glucokinase (GK) is a key regulator of glucose homeostasis. Method: Based on structure-based design strategies, a series of novel orotic acid amide derivatives have been synthesized. Lead optimization led to the discovery of several active compounds via in vitro enzyme assays. Compared to the positive control compound GKA22, compounds 10j, 11h and 11i exhibited identical or even higher activity. Furthermore, docking simulation of compound 11i further demonstrated that the hydrogen atom of amide and the nitrogen atom of pyrimidine both bound to Arg63 via hydrogen bonds. Results: Hydrogen bond interactions were also observed between the two oxygen atoms of 2-methoxy-1-methyl-ethoxy moiety and Thr65. Both ends of the molecule were fixed in allosteric pocket of glucokinase, which was in favour of keeping active conformation.

4-(PYRAZOL-3-YLAMINO) PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER

A compound of Formula (I); wherein the substituents are as defined in the text for use in modulating insulin-like growth factor 1 receptor activity in a warm blooded animal such as man.